You are here

Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK100183-01
Agency Tracking Number: R43DK100183
Amount: $224,700.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
400 Riverhills Business Park
BIRMINGHAM, AL 35242-8101
United States
DUNS: 807018333
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (205) 307-6535
Business Contact
Phone: (205) 918-8138
Research Institution

DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen synthetic organic small molecule collections on differentiated human adipocyte platforms to discover a newclass of therapeutic drugs for type 2 diabetes mellitus (T2DM) and obesity. Differentiated human adipocytes from visceral (central abdominal depot) origin are challenged with test compounds to discover hit small molecules that trigger the secretion of endogenous adiponectin. Adiponectin is an established biomarker and causative mediator in obesity-related diseases. Plasma concentrations of this adipokine are reduced in vivo in obese and diabetic patients. Accordingly, up-regulating endogenous adiponectin expression and secretion has been proposed as a high-priority therapeutic strategy for obesity-related diseases. The ultimate goal of this work is to develop, optimize, validate and implement the human fat cell-driven drug discovery platform based on immortalized and primary human visceral adipocytes to discover novel adiponectin secretagogues for obesity, diabetes and related metabolic diseases as well as ailments that arise from secondary complications of metabolic disease. The key ingredient in this program is DBM's core principle of using biologically- and disease-relevant human cellular platforms to 'de-risk' de novo drug discovery programs. This core principle reflects DBM's unique angle, approach and offering to the drug discovery space. Primary and immortal human pre-adipocytes from normal donors and type 2 diabetes mellitus patients are differentiated by a patent-protected process that employs a novel differentiation medium. It is DBM's view that successful de novo drug discovery programs must utilizea disease-relevant human cell platform and a disease-relevant target/phenotypic endpoint (i.e. human adipocytes secreting human adiponectin). Obesity and obesity-related diseases including T2DM, atherosclerosis, cardiovascular disease, fatty liver disease,and diabetic hyperglycemic injury of the eye, heart, kidney and peripheral nerves have reached epidemic proportions in the US and the developed world and exact huge morbidity and cost burdens on society. An enormous unmet clinical need exists for new therapeutic drugs to combat these diseases, especially in Alabama where DBM resides in the heart of the Southeastern Diabetes Belt. Drug pipelines for metabolic diseases are in peril, with most pipeline drugs for obesity-related diseases simply re-branded, re-purposed or combined because of an undefined weight loss side effect. Many of these new or re-purposed drug classes for metabolic diseases have failed and been abandoned recently. There is dire need and window of opportunity to re-kindle the metabolic diseases drug discovery effort with novel and innovative programs. DBM rises to that unmet need with the following major project milestones that: (1) Establish a robust differentiated human visceral adipocyte drug discovery platform; (2) Design, optimize andimplement a primary de novo drug discovery HTS-friendly bioassay; (3) Screen the 60,000 synthetic organic compounds within the DBM molecular library to discover novel endogenous adiponectin secretagogues; (4) Validate putative hits from the primary HTS bioassay with a robust Critical Path; and (5) Perform chemoinformatics on the validated hit compounds to identify hit-to-lead chemical classes worthy of deeper assessment and profiling. DBM is already 10% of the way to this screening goal and has already performed validation and chemoinformatics on the early output from our Critical Path. DBM seeks SBIR funds to deepen and accelerate this critical metabolic diseases drug discovery program. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Obesity, diabetes, related metabolic disorders and secondary diabetic injury of additional body organs and tissues (eye, heart, kidney and nerves) are epidemics in danger of becoming a global pandemic. The combination of high-calorie fast food intake (unhealthy diet) and a computer-based workforce coupled with social networking and the video game industry (sedentary lifestyle) have combined to cause 2 billion adults and millions of children worldwide to be overweight or obese. The future human health burden is immense and potentially catastrophic. The cost for the US alone is estimated to exceed 1 trillion by 2015. The cost worldwide is 10-20X that amount. Metabolic disease incidence in Alabama is affecting the entire local society. Discovery BioMed, Inc. resides inthe heart of the Southeastern Diabetes Belt and feels that it has a duty as the only specialty humanized drug Discovery Company in the region to devote any and all resources to discovering new and specific classes of small molecule therapeutic drugs for obesity and diabetes. This disease umbrella is one of three strategic foci for the company and we are employing multiple angles and methods to combat these metabolic diseases that will likely require a multi-drug and biologic cocktail or regimen to be successful in disease control and cure.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government